
358: FDA's gene therapy turmoil, and an alternative model for funding research
The Readout Loud
00:00
FDA Leadership Shifts and Gene Therapy Challenges
This chapter explores the recent upheaval at the FDA, focusing on the departure of key personnel and its impact on cell and gene therapy regulation. It discusses the tensions between expedited drug approvals, scientific integrity, and the introduction of a new pilot program for faster reviews amid concerns of political influence.
Transcript
Play full episode